drugset / Trial / NCT01013675

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

NCT01013675

Phase 2 Completed 622 enrolled Abbott Biologicals Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.

Timeline

Start
2009-11
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine Vaccine 15 ug
Comparator Influenza Virus Vaccine Vaccine 0.5 ml

Indications

No indication recorded.